Autologous hematopoietic stem cell transplant (HSCT) recipients tend to have fewer infectious complications than allogeneic transplant recipients; however, defects in cell-mediated immunity can continue for months, even in uncomplicated HSCTs of both types. Patients undergoing transplantation are at high risk for infection with a variety of pathogens at multiple phases in their care. This section includes evidence for preventing infections in the transplant patient population.
Have a question about how to apply this PEP topic to your practice? Ask a nurse on ONS staff at email@example.com.